Richard Silvera1, Tyler Martinson2, Michael M Gaisa1, Yuxin Liu3, Ashish A Deshmukh4, Keith Sigel5. 1. Division of Infectious Diseases, Department of Medicine. 2. Department of Medical Education. 3. Department of Pathology. 4. Department of Management, Policy and Community Health, University of Texas School of Public Health, Houston, TX, USA. 5. Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
BACKGROUND: Anal cancer disproportionately affects people with HIV (PWH). High-grade squamous intraepithelial lesions (HSIL) are cancer precursors and treating them might prevent anal cancer. Data on adherence to HSIL treatment and surveillance is limited but needed to identify deficiencies of screening strategies. METHODS: We collected data on high-resolution anoscopy (HRA) attendance and outcomes from 2009 to 2019 in a large urban anal cancer-screening program. Patients with an initial HSIL diagnosis were followed for return for HSIL electrocautery ablation within 6 months of index HSIL diagnosis, and follow-up HRA within 18 months of index HSIL diagnosis. We also evaluated predictors of these outcomes in univariable and multivariable analyses. RESULTS: One thousand one hundred and seventy-nine unique patients with an anal HSIL diagnosis were identified and 684 (58%) returned for electrocautery ablation. Of those treated, only 174 (25%) and only 9% of untreated HSIL patients (47 of 495) underwent surveillance HRA within 18 months of index HSIL diagnosis. In multivariable analyses, black patients and PWH regardless of virologic control were less likely to undergo HSIL ablation within 6 months of HSIL diagnosis whereas patients with commercial insurance were more likely to be treated within 6 months of diagnosis. Among treated HSIL patients, PWH with viremia had a lower likelihood of engaging in post-treatment surveillance within 18 months of HSIL diagnosis. DISCUSSION: Even in large specialized anal cancer screening programs adherence to HSIL treatment and surveillance is low. Psychosocial and economic determinants of health may impact retention in care. Addressing both personal and structural barriers to patient engagement may improve the effectiveness of anal cancer screening.
BACKGROUND: Anal cancer disproportionately affects people with HIV (PWH). High-grade squamous intraepithelial lesions (HSIL) are cancer precursors and treating them might prevent anal cancer. Data on adherence to HSIL treatment and surveillance is limited but needed to identify deficiencies of screening strategies. METHODS: We collected data on high-resolution anoscopy (HRA) attendance and outcomes from 2009 to 2019 in a large urban anal cancer-screening program. Patients with an initial HSIL diagnosis were followed for return for HSIL electrocautery ablation within 6 months of index HSIL diagnosis, and follow-up HRA within 18 months of index HSIL diagnosis. We also evaluated predictors of these outcomes in univariable and multivariable analyses. RESULTS: One thousand one hundred and seventy-nine unique patients with an anal HSIL diagnosis were identified and 684 (58%) returned for electrocautery ablation. Of those treated, only 174 (25%) and only 9% of untreated HSIL patients (47 of 495) underwent surveillance HRA within 18 months of index HSIL diagnosis. In multivariable analyses, black patients and PWH regardless of virologic control were less likely to undergo HSIL ablation within 6 months of HSIL diagnosis whereas patients with commercial insurance were more likely to be treated within 6 months of diagnosis. Among treated HSIL patients, PWH with viremia had a lower likelihood of engaging in post-treatment surveillance within 18 months of HSIL diagnosis. DISCUSSION: Even in large specialized anal cancer screening programs adherence to HSIL treatment and surveillance is low. Psychosocial and economic determinants of health may impact retention in care. Addressing both personal and structural barriers to patient engagement may improve the effectiveness of anal cancer screening.
Authors: Ashish A Deshmukh; Ryan Suk; Meredith S Shiels; Kalyani Sonawane; Alan G Nyitray; Yuxin Liu; Michael M Gaisa; Joel M Palefsky; Keith Sigel Journal: J Natl Cancer Inst Date: 2020-08-01 Impact factor: 13.506
Authors: Elizabeth A Stier; Wafaa Abbasi; Amma F Agyemang; Eduardo Amílkar Valle Álvarez; Elizabeth Y Chiao; Ashish A Deshmukh Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.731
Authors: Kaan Z Apaydin; Andy Nguyen; Christina P C Borba; Derri L Shtasel; Sharon Ulery; Kenneth H Mayer; Alex S Keuroghlian Journal: Sex Transm Infect Date: 2018-06-22 Impact factor: 3.519
Authors: Gary M Clifford; Damien Georges; Meredith S Shiels; Eric A Engels; Andreia Albuquerque; Isobel Mary Poynten; Alexandra de Pokomandy; Alexandra M Easson; Elizabeth A Stier Journal: Int J Cancer Date: 2020-07-29 Impact factor: 7.396